SillaJen, a privately held biotherapeutics company focused on development of targeted oncolytic immunotherapy products for cancer, has completed its name change to SillaJen Biotherapeutics following its acquisition of Jennerex Biotherapeutics.

SillaJen's lead product Pexa-Vec (formerly JX-594) demonstrated an overall survival benefit in a randomized dose-finding phase II trial for liver cancer, and plans are underway to enter phase III in first-line hepatocellular carcinoma patients in 2015.

"Completing our name change to SillaJen Biotherapeutics solidifies the merger of these two exciting companies and helps unite us as one company with one mission, which is to develop groundbreaking therapeutics that offer new hope for patients with life-threatening cancers," said David McDonald, chief business officer of SillaJen.